Objectives: To develop and validate a gout flare risk stratification tool for people with gout hospitalized for non-gout conditions.
Methods: The prediction rule for inpatient gout flare was derived from a cohort of 625 hospitalized people with comorbid gout from New Zealand. The rule had four items: no pre-admission gout flare prophylaxis, no pre-admission urate-lowering therapy, tophus and pre-admission serum urate >0.36 mmol/l within the previous year (GOUT-36 rule). Two or more items are required for the classification of high risk for developing inpatient gout flares. The GOUT-36 rule was validated in a prospective cohort of 284 hospitalized people with comorbid gout from Thailand and China.
Results: The GOUT-36 rule had a sensitivity of 75%, specificity of 67% and area under the curve of 0.71 for classifying people at high risk for developing inpatient gout flares. Four risk groups were developed: low (no items), moderate (one item), high (two items) and very high risk (three or four items). In a population with frequent (overall 34%) in-hospital gout flares, 80% of people with very high risk developed inpatient flares while 11% with low risk had inpatient flares.
Conclusion: The GOUT-36 rule is simple and sensitive for classifying people with high risk for inpatient gout flares. The rule may help inform clinical decisions and future research on the prevention of inpatient gout flares.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/rheumatology/keab590 | DOI Listing |
J Rheumatol
January 2025
LKS: Rheumatologist, MBChB, FRACP, PhD, Department of Rheumatology, Immunology and Allergy, Rheumatology Registrar Te Whatu Ora Waitaha, New Zealand and Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
Objective: Despite effective treatment, gout is poorly managed. The aim of this study was to determine rates of serum urate (SU) testing and allopurinol dose adjustment in patients on allopurinol admitted to Christchurch based hospitals.
Methods: The hospital electronic prescribing and administration (ePA) system was used to identify patients on allopurinol during hospital admissions from March 2016-March 2023.
J Health Econ Outcomes Res
January 2025
Ultragenyx Pharmaceutical Inc., Novato, CA, USA.
Glycogen storage disease type Ia (GSDIa) is a rare inherited disorder resulting in potentially life-threatening hypoglycemia, metabolic abnormalities, and complications often requiring hospitalization. This retrospective database analysis assessed the complications, resource utilization, and costs in a large cohort of patients with GSDIa. We conducted a retrospective cohort study of GSDIa patients and matched non-GSDIa comparators utilizing the PharMetrics® Plus database.
View Article and Find Full Text PDFBMJ Open
November 2024
Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China
Int J Gynaecol Obstet
November 2024
Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada.
South Med J
September 2024
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!